Kadimastem and iTolerance Announce Breakthrough Treatment for Type 1 Diabetes
Kadimastem and iTolerance Announce Breakthrough Treatment for Type 1 Diabetes
Key Takeaways (TLDR)
Kadimastem announces positive results of innovative diabetes treatment, potentially giving them a competitive edge in the field.
The treatment combines immune modulator microgel material and insulin-producing islet cells derived from human stem cells, showing effectiveness in restoring normoglycemia.
The innovative treatment offers hope for a cure for Type 1 Diabetes without the need for life-long immunosuppression, potentially improving the lives of diabetes patients.
The combination therapy reverses diabetes and preserves the functional integrity of the transplanted stem cell-derived islets, marking a significant breakthrough in diabetes research.
Why it Matters
The announcement of the breakthrough treatment for type 1 diabetes is a significant development in the field of diabetes research and treatment. The innovative approach, recognized by the Diabetes Research Institute at the University of Miami, offers hope for the potential cure of insulin-dependent diabetes without the need for life-long immunosuppression. This has the potential to revolutionize diabetes treatment and improve the quality of life for millions of people worldwide who are living with the disease.
Summary
Kadimastem Ltd. (TASE: KDST) and iTolerance Inc. jointly announced positive results of their leading diabetes product at the 84th scientific conference of the American Diabetes Association. The product, a combination of an immune modulator microgel material and insulin-producing islet cells derived from human stem cells, demonstrated functional insulin release and disease reversal in a model of diabetes. The treatment was recognized by the Diabetes Research Institute at the University of Miami School of Medicine as an innovative approach for the treatment of type 1 diabetes. The study's key findings indicate that this combination therapy reverses diabetes and preserves the functional integrity of the transplanted stem cell-derived islets.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Kadimastem and iTolerance Announce Breakthrough Treatment for Type 1 Diabetes.